Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Nizar M TannirDaniel C ChoAdi DiabMario SznolMehmet Asim BilenArjun V BalarGiovanni GrignaniErika PuenteLily TangDavid ChienUte HochArkopal ChoudhuryDanni YuSue L CurrieMary A TagliaferriJonathan ZalevskyArlene O Siefker-RadtkeMichael E HurwitzPublished in: Journal for immunotherapy of cancer (2022)
BEMPEG plus NIVO showed preliminary antitumor activity as first-line therapy in patients with advanced clear-cell RCC and was well tolerated. These findings warrant further investigation.
Keyphrases